|
gptkbp:instanceOf
|
gptkb:Corticosteroid
|
|
gptkbp:administeredBy
|
oral route
topical application
intramuscular injection
intravenous injection
ophthalmic route
|
|
gptkbp:ATCCode
|
gptkb:H02AB02
|
|
gptkbp:brand
|
gptkb:Ozurdex
gptkb:Decadron
gptkb:DexPak
gptkb:Maxidex
|
|
gptkbp:CASNumber
|
gptkb:50-02-2
|
|
gptkbp:contraindication
|
hypersensitivity to dexamethasone
systemic fungal infection
|
|
gptkbp:discoveredBy
|
gptkb:Philip_Showalter_Hench
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:drugClass
|
gptkb:immunosuppressant
gptkb:Corticosteroid
gptkb:anti-inflammatory_agent
|
|
gptkbp:eliminationHalfLife
|
36-54 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C22H29FO5
|
|
gptkbp:includedIn
|
gptkb:World_Health_Organization's_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
topical
intramuscular
intravenous
intra-articular
intralesional
intravitreal
ophthalmic
|
|
gptkbp:sideEffect
|
gptkb:bone
hypertension
mood changes
weight gain
insomnia
increased appetite
hyperglycemia
increased risk of infection
|
|
gptkbp:usedFor
|
immunosuppression
treatment of COVID-19
anti-inflammatory therapy
treatment of asthma
treatment of cerebral edema
treatment of certain cancers
treatment of croup
treatment of severe allergies
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_pandemic
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dexamethasone
|